Labiotech.eu

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Korean researchers develop antimicrobial peptides discovery tool

Antimicrobial peptides (AMPs) are a promising new weapon for combating the growing antimicrobial resistance (AMR) of bacteria and other harmful microorganisms. Now, researchers from the Gwangju Institute of Science and Technology (GIST) in South Korea have developed a new, easy-to-interpret AI-powered AMP prediction model. The tool, named AMP-BERT, can capture the functional and structural properties […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the closing of an oversubscribed $135 million Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well […]

February 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

HKUMed develops nanoparticle-based targeted drug delivery system

A research team from LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed thyroid hormone (TH) – encapsulated nanoparticles modified with adipose-homing peptide, which selectively transport TH to adipose tissues. The researchers say this will advance the treatment of obesity-related medical complications with TH by overcoming its severe adverse effects caused by […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Can CRISPR correct type 2 diabetes gene?

Swedish researchers have identified 395 genes that are differently expressed in people with type 2 diabetes. One of these (PAX5) has proven to be very strongly associated with impaired insulin secretion. Now, researchers want to investigate if it is possible to use the genetic CRISPR/Cas9 scissors to correct the gene’s activity. The research team’s scientific […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

New event set to take place in Swedish biotech hub

A new event, which will include presentations by Nobel laureates, is set to showcase the best of pharmacology. The Lund Spring Symposium, which takes place from May 24 to 26 at the Palaestra et Odeum in Lund, Sweden, aims to raise the profile of pharmacology as a cross-functional discipline in the 21st Century and to […]

February 21, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

First patient enrolled in Pharming APSD trial

Pharming Group N.V. says the first patient has been enrolled in its phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants. At […]

February 21, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Biocytogen launches nanobody therapeutics project for 100 targets

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has launched the “Nano 100 Project,” which aims to develop fully human nanobody drugs for more than 100 targets. The project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale. Compared […]

February 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

FDA approves alpha-mannosidosis drug

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), says the U.S. Food and Drug Administration (FDA) has approved Lamzede (velmanase alfa-tycv) for the treatment of non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and pediatric patients. AM is an ultra-rare, progressive lysosomal storage disorder […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

From breast to bone: Refining metastasis drug discovery with a novel organ-on-a-chip device

Understanding invasive cancer progression and metastasis formation are among the core open questions in cancer research. However, the limitations of current models lead to high failure rates in drug development. An EU-funded consortium has designed an organ-on-a-chip approach that could deliver new insights. In metastasis, circulating tumor cells spontaneously shed from the primary site to […]

February 21, 2023 - 6 minutesmins - By Ute Boronowsky

CAR-T cell therapy, cancer therapy, cell therapy

Interview 17 Feb 2023

The benefits – and challenges – of in-house CAR T-cell therapy

The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better […]

February 17, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 17 Feb 2023

Positive results for INOVIO recurrent respiratory papillomatosis trial

INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated recurrent respiratory papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Korean researchers develop antimicrobial peptides discovery tool

Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders

HKUMed develops nanoparticle-based targeted drug delivery system

Can CRISPR correct type 2 diabetes gene?

New event set to take place in Swedish biotech hub

First patient enrolled in Pharming APSD trial

Biocytogen launches nanobody therapeutics project for 100 targets

FDA approves alpha-mannosidosis drug

From breast to bone: Refining metastasis drug discovery with a novel organ-on-a-chip device

The benefits – and challenges – of in-house CAR T-cell therapy

Positive results for INOVIO recurrent respiratory papillomatosis trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!